medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 1

<< Back Next >>

Ann Hepatol 2004; 3 (1)

Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2

Catania VA, Sánchez PEJ, Luquita MG, Ruiz ML, Villanueva SSM, Jones B, Mottino AD

Language: English
References: 82
Page: 11-17
PDF size: 90.17 Kb.


Text Extraction

Treatment of experimental animals with prototypical enzyme inducers represents a useful tool to characterize the role of different isozymes in drug metabolism and to improve our knowledge on factors regulating their synthesis at the transcriptional level. The effect of model enzyme inducers on phase II (conjugating) enzyme families, including UDP-glucuronosyltransferase’s and glutathione-S-transferase’s, has been well characterized in rodent liver. More recently, the effect of inducers on the expression of canalicular multidrug resistance-associated protein 2 (Mrp2) has been focused upon. The identification of a number of conjugated drugs as Mrp2 substrates suggests that both the conjugation and transport systems act coordinately to improve drug elimination from the body. We provide evidence about circumstances resulting in the simultaneous upregulation of phase II enzymes and Mrp2 in hepatic and extrahepatic tissues, most likely involving activation of common nuclear receptors (e.g. FXR, PXR). Additionally, we provide an analysis of examples of drug-induced toxicity leading to the simultaneous downregulation of both systems. Potential therapeutic strategies based on the modulation of expression of these systems are also briefly commented upon.


REFERENCES

  1. Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 1997; 378: 787-91.

  2. Leier I, Hummel-Eisenbeiss J, Cui Y, Keppler D. ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 2000; 57: 1636-42.

  3. Mottino AD, Hoffman T, Jennes T, Vore M. Expression and localization of Multidrug resistant protein mrp2 in rat small intestine. J Pharm Exp Ther 2000; 293: 717-23.

  4. Laitinen M, Watkins JB. Mucosal biotransformations. In: Rozman K and Hanninen O eds. Gastrointestinal Toxicology. Chapter 6. Amsterdam; Elsevier 1986; 169-92.

  5. Klaassen CD, Watkins JB. Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 1984; 36: 1-67.

  6. Koster AS, Frankhuizen-Sierevogel C, Noordhoek J. Glucuronidation of morphine and six beta 2-sympathomimetics in isolated rat intestinal epithelial cells. Drug Metab Dispos 1985; 13: 232-38.

  7. Lin JH, Chiba M, Baillie TA. Is the role of the intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-57.

  8. Mannervik B, Danielson UH. Glutathione transferases-structure and catalytic activity. CRC Crit Rev Biochem 1988; 23: 283-337.

  9. Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi T, Jansen PLM, Lancet D, Mulder GJ, Roy Chowdhury J, Siest G, Tephly TR, Mackenzie PI. The UDP-Glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991; 10: 487-94.

  10. Hayes JD, Pulford DJ. The glutathione S-Transferase Supergene Family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. CRC Crit Rev Biochem 1995; 30: 445-600.

  11. Meech R, Mackenzie PI. Structure and function of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol 1997; 24: 907-15.

  12. Iwamoto K, Klaassen CD. First-pass effect of morphine in the rats. J Pharmacol Exp Ther 1977; 200: 236-44.

  13. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-19.

  14. Schwenk M, Schiemenz C, Lopez del Pino V, Remmer H. First-pass biotransformation of Ethinylestradiol in rat small intestine in situ. Naunyn Schmiedeberg’s Arch Pharmacol 1982; 321: 223-25.

  15. Mulder GJ. Glucuronidation and its role in regulation of biological activity of drugs. Annu Rev Pharmacol Toxicol 1992; 32: 25-49.

  16. Wildt SN, Kearns GL, Leeder JS, van der Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Phamacokinet 1999; 36: 439-52.

  17. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, Keppler DSO. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 1999; 30: 485-90.

  18. Dietrich CG, de Waart R, Ottenhoff R, Bootsma AH, van Gennip AH, R. Oude Elferink R. Impaired biliary and intestinal excretion of PhIP, an abundant food-derived carcinogen, in the MRP2-deficient rat. Carcinogenesis 2001; 22: 805-11.

  19. Paulusma CC, Kothe MJC, Bakker CTM, Bosma PJ, van Bokhoven I, van Marle J, Bolder U, Tytgat GNJ, Oude Elferink RPJ. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 2000; 31: 684-93.

  20. Chowdhury JR, Novikoff PM, Chowdhury NR, Novikoff AB. Distribution of UDP-glucuronosyltransferase in rat tissue. Proc Natl Acad Sci USA 1985; 82: 2990-94.

  21. Schaub TP, Kartenbeck J, König J, Vogel O, Witzgall R, Kriz W, Keppler D. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 1977; 8: 1213-21.

  22. Peters WHM, Allebes WA, Jansen PLM, Poels LG, Capel PJA. Characterization and tissue specificity of a monoclonal antibody against human uridine 5'-diphosphate-glucuronosyltransferase. Gastroenterology 1987; 93: 162-69.

  23. Schaub TP, Kartenbeck J, König J, Spring H, Dörsam J, Staehler G, Störkel S, Thon WF, Keppler D. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999; 10: 1159-69.

  24. Clifton G, Kaplowitz N. The glutathione S-transferases of the small intestine in the rat. Cancer Res 1977; 37: 788-791.

  25. Schwarz LR, Schwenk M. Sulfation in isolated enterocytes of guinea pig: dependence on inorganic sulfate. Biochem Pharmacol 1984; 33: 3353-56.

  26. Koster AS, Frankhuijzen-Sierevolgel AC, Noordhoek J. Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. Biochem Pharmacol 1985; 34: 3527-32.

  27. Jeynes BJ, Altmann GG. A region of mitochondrial division in the epithelium of the small intestine of the rat. Anat Rec 1975; 182: 289-95.

  28. Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002; 302: 407-15.

  29. Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V. Regulation of biliary durg efflux pump expression by hormones and xenobiotics. Toxicology 2001; 167: 37-46.

  30. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett 2001; 120: 51-57.

  31. Liddle C, Goodwin B. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin Liver Dis 2002; 22: 115-22.

  32. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocrine Rev 2002; 23: 687-02.

  33. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62: 638-46.

  34. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001; 41: 123-43.

  35. Schuetz EG, Brimer C, Schuetz JD. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol 1998; 54: 1113-17.

  36. Igarashi T, Irokawa N, Ono S, Ohmori S, Ueno K, Kitagawa H. Difference in the effects of phenobarbital and 3-methylcholanthrene treatment on subunit composition of hepatic glutathione S-transferase in male and female rats. Xenobiotica 1987; 17: 127-37.

  37. Ding VDH, Pickett, CB. Transcriptional regulation of rat liver glutathione S-transferase genes by phenobarbital and 3-methylcholanthrene. Arch Biochem Biophys 1985; 240: 553-59.

  38. Bock KW, Bock-Henning BS. Differential induction of human liver UDP-glucuronosyltransferase activities by phenobarbital-type inducers. Biochem Pharmacol 1987; 36: 4137-43.

  39. Mottino AD, Guibert EE, Rodríguez Garay EA. Additive effect of combined spironolactone and phenobarbital treatment on hepatic bilirubin UDP-glucuronyltransferase. Biochem Pharmacol 1989; 38: 851-53.

  40. Emi Y, Ikushiro S, Iyanagi T. Drug-responsive and tissue-specific alternative expression of multiple first exons in rat UDP-glucuronosyltransferase family 1 (UGT1) gene complex. J Biochem (Tokyo) 1995; 117: 392-99.

  41. Ikushiro S, Emi Y, Iyanagi T. Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti-peptides antibodies. Arch Biochem Biophys 1995; 324: 267-72.

  42. Wong BK, Fei P, Kong A-N T. Differential induction of UDP-glucuronosyl- transferase activity and gene expression in rat liver. Pharmaceut Res 1995; 12: 1105-08.

  43. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M, Sueyoshi T. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 2001; 33: 1232-38.

  44. Johnson DR, Habeebu SSM, Klaassen CD. Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. Toxicol Sci 2002; 66: 16-26.

  45. Watkins JB, Gregus Z, Thompson Z, Klaassen CD. Induction studies on the functional heterogeneity of rat liver UDP-glucuronosyltransferases. Toxicol Appl Pharmacol 1982; 64: 439-46.

  46. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer SA , Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277: 2908-15.

  47. Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han Y-H, Jansen PLM, Meier PJ, Steiger B, Brouwer KLR. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 2003; 64: 154-59.

  48. Hagenbush N, Reichel C, Steiger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. H Hepatol 2001; 34: 881-87.

  49. Falkner KC, Pinaire JA, Xiao G-H, Geoghegan TE, Prough RA. Regulation of the rat glutathione S-transferase A2 gene by glucocorticoids: involvement of both the glucocorticoid and pregnane X receptors. Mol Pharmacol 2001; 60: 611-19.

  50. Chen C, Staudinger JL, Klaassen CD. Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltransferases in mouse liver by pregnenolone-16a-carbonitrile. Drug Metab Dispos 2003; 31: 908-15.

  51. Mottino AD, Rassero JA, Rodríguez Garay EA. Effect of spironolactone on bilirubin conjugation by the rat liver. Biochem Pharmacol 1979; 28: 2215-17.

  52. Morisoli LS, Mottino AD, Pellegrino JM, Guibert EE, Rodríguez Garay EA. Effect of spironolactone on bilirubin metabolism in rat liver and small intestinal mucosa. Biochem Pharmacol 1982; 31: 1469-74.

  53. Catania VA, Luquita MG, Sánchez Pozzi EJ, Mottino AD. Differential induction of glutathione S-transferase subunits by spironolactone in rat liver, jejunum and colon. Life Sci 998; 63: 2285-93.

  54. Catania VA, Luquita, MG, Sánchez Pozzi EJ, Ikushiro S, Emi T, Iyanagi T, Mottino AD. Effect of spironolactone on the expression of rat hepatic UDP-glucuronosyltransferase. Biochem. Pharmacol 2003; 66: 171-77.

  55. Xie W, Yeuh M-F, Radominska-Pandya A, Saini SPS, Negishi Y, Bottroff BS, Cabrera GY, Tukey RH, Evans RM. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 2003; 100: 4150-55.

  56. Catania VA, Luquita MG, Sánchez Pozzi EJ, Pellegrino JM, Ochoa JE, Mottino AD. Induction of hepatic and intestinal multidrug resistance-associated protein 2 by spironolactone. J Hepatol 2002; 36 (Suppl. 1, Abst. 903), 251.

  57. Johnson DR, Klaassen CD. Regulation of multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicol Sci 2002; 67: 182-89.

  58. Bock KW, Eckle T, Ouzzine M, Fournel-Gigleaux S. Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump mrp2 (multidrug resistance protein 2) in caco-2 cells. Biochem Pharmacol 2000; 59: 467-70.

  59. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, Moore DD. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 2003; 100: 4156-61.

  60. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL. The rat canalicular conjugate export pump (Mrp2) in down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113: 255-64.

  61. Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen PLM, Oude Elferink RPJ. Impaired hepatocanalicular organic anion transport in endotoxemic rats. Am J Physiol 1995; 269: G247-34.

  62. Bolder U, Ton-Nu HT, Schteingart C, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 1997, 112: 214-25.

  63. Trauner M, Nathanson MH, Rydberg SA, Koeppel TA, Gastung C, Sessa WC, Boyer JL. Endotoxin impairs biliry glutathione and HCO3- excretion and blocks the choleretic effect of nitric oxide in rat liver. Hepatology 1997; 25: 1184-91.

  64. Vore M. Estrogen cholestasis: membranes, metabolites, or receptors? Gastroenterology 1987; 93: 643-49.

  65. Bossard R, Stieger B, O’Neill B, Fricker G, Meier PJ. Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 1993; 91: 2714-20.

  66. Reyes H, Simon F. Intrahepatic cholestasis of pregnanacy: and estrogen-related disease. Semin Liver Dis 1993; 13: 289-301.

  67. Crocenzi FA, Sánchez Pozzi EJ, Pellegrino JM, Favre CO, Rodríguez Garay EA, Mottino AD, Coleman R, Roma MG. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 2001; 34: 329-39.

  68. Oude Elferink RPJ, Jansen PLM. The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacol Ther 1994; 64: 77-97.

  69. Bengoechea L, Ouviña G, Lemberg A. Liver microsomal bilirubin UDP-glucuronsyltransferase disturbances in bile duct ligated rats. Biochem Biophys Res Commun 1985; 130: 163-67.

  70. Alptekin N, Mehmetçik G, Uysal M, Aykaç-Toker G. Evidence for oxidative stress in the hepatic mitochondria of bile duct ligated rats. Pharmacological Research 1997; 36: 243-47.

  71. Choi S, Kim S. Lipopolysaccharide inhibition of rat hepatic microsomal epoxide hydrolase and glutathione S-transferase gene expression irrespective of nuclear factor kB activation. Biochem Pharmacol 1998; 56: 1427-36.

  72. Watson AM, Warren G, Howard G, Shedlofsky SI, Blouin RA. Activities of conjugating and antioxidant enzymes following endotoxin exposure. J Biochem Mol Toxicol 1999; 13: 63-69.

  73. Sánchez Pozzi EJ, Crocenzi FA, Pellegrino JM, Catania VA, Luquita MG, Roma MG,. Rodríguez Garay EA, Mottino AD. Ursodeoxycholate reduces ethynylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis J Pharmacol Exp Ther 2003; 306: 279-86.

  74. Meyers M, Slikker W, Pascoe G, Vore M. Characterization of cholestasis induced by estradiol-17b-D-glucuronide in the rat. J Pharmacol Exp Ther 1980; 214: 887–93.

  75. Geier A, Kietrich C, Voigt S, Kim S, Gerloff T, Kullak-Ubick G, Lorenzen J, Matern S, Gastung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 2003; 38: 345-54.

  76. Maheo K, Antras-Ferry J, Morel F, Langouët S, Guillouzo A. Modulation fo glutathione S-transferase subunits A2, M1 and P1 expression by interleukin-1b in rat hepatocytes in primary culture. J Biol Chem 1997; 272: 16125-32.

  77. Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 in cholestatic rat liver. Hepatology 2001; 34: 35159.

  78. Miguet JP, Vuitton D, Thebault-Lucas A, Joanne C, Dhumeaux D. Spironolactone and enzyme induction in patients with alcoholic cirrhosis. Gastroenterology 1980; 78: 996-1000.

  79. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-80.

  80. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001; 121:170-83.

  81. Paolini M, Pozzetti L, Montagnani M, Potenza G, Sabatini L, Antelli A, Cantelli-Forti G, Roda A. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities. Hepatology 2002; 36: 305-14.

  82. Rost D, Herrmann T, Sauer P, Schmidts H, Stieger B, Meier P, Stremmel W, Stiehl A. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate. Hepatology 2003; 38: 187-95.




2020     |     www.medigraphic.com